A novel T4- and λ-based receptor binding protein family for bacteriophage therapy host range engineering.

ABSTRACT: Widespread multidrug antimicrobial resistance in emerging pathogens has led to a renewed interest in phage therapy as an alternative or supplement to traditional small molecule drugs. The primary limiting factors of phage therapy deployment rest in the narrow host range specificity of phage as well as a poor understanding of many phages' unintended downstream effects on host physiology and microbiota as well as on adverse pathogen evolution. Consequently, this has made assembling well-defined and safe "phage-cocktails" of solely naturally occurring phages labor- and time-intensive. To increase the speed, efficacy, and safety of therapeutic deployment, there is exceptional interest in modulating the host ranges of well-characterized lytic phages (e.g., T4 and T7) by using synthetic strategi

SUBMITTER: Magaziner SJ 

PROVIDER: S-EPMC9659904 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature